Valuation: Shamrock Industrial Company Limited

Market Cap 116M 1.23M 1.08M 994K 930K 1.74M 1.78M 11.94M 4.62M 57.33M 4.62M 4.52M 199M P/E 2024
-128x
P/E 2025 -53.4x
Enterprise Value 116M 1.23M 1.08M 993K 929K 1.74M 1.78M 11.93M 4.62M 57.26M 4.61M 4.51M 199M EV / Sales 2024
38,257,531x
EV / Sales 2025 -
Free-Float
48.09%
Yield 2024 *
-
Yield 2025 -
05-29 Shamrock Industrial Company Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 CI
02-12 Shamrock Industrial Company Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
12-22 Shamrock Industrial Company Limited Approves the Proposals for Incorporation of Wholly Owned Subsidiaries CI
12-22 Shamrock Industrial Company Limited Approves the Proposals for Incorporation of Wholly Owned Subsidiaries CI
12-11 Shamrock Industrial Company Limited Announces Incorporation of Wholly Owned Subsidiary HODL Energy Private Limited in India CI
11-14 Shamrock Industrial Company Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025 CI
11-12 Lotus Excel Wealth Creators LLP, HODL Systems LLP, Bagepalli Vijaykumar Harish and Rattan Kapoor completed the acquisition of 0.38% stake in Shamrock Industrial Company Limited for INR 0.34 million. CI
25-10-28 Shamrock Industrial appoints Rahul Manoj Rajani as chief financial officer RE
25-10-28 Shamrock Industrial Company Limited Approves Appointment of Rahul Manoj Rajani as Chief Financial Officer, Effective October 28, 2025 CI
25-10-28 Shamrock Industrial Company Limited Announces Board Appointments, Effective October 28, 2025 CI
25-10-16 Shamrock Industrial Company Limited Announces Resignation of Jitesh Rameshchandra Khokhani as Chief Financial Officer, with Effect from Closure of Business Hours of October 16, 2025 CI
25-10-16 Shamrock Industrial Company Limited Announces Board Resignations, with Effect from October 16, 2025 CI
25-08-12 Shamrock Industrial Company Limited Reports Earnings Results for the First Quarter Ended June 30, 2025 CI
Current month+4.99%
1 month+4.99%
3 months+10.20%
6 months+21.44%
Current year+21.44%
1 week 23.56
Extreme 23.56
23.56
1 month 22.44
Extreme 22.44
23.56
Current year 19.4
Extreme 19.4
23.56
1 year 15.98
Extreme 15.98
23.56
3 years 3.34
Extreme 3.34
23.56
5 years 3.16
Extreme 3.16
23.56
10 years 3.16
Extreme 3.16
23.56
Manager TitleAgeSince
Chief Executive Officer - 2025-10-15
Director of Finance/CFO - 2025-10-27
Chief Operating Officer - 2025-10-27
Director TitleAgeSince
Director/Board Member - 2021-06-21
Director/Board Member - 2022-04-20
Director/Board Member - 2025-10-15
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%+47.43%+363.78% 1.35M
+7.13%+9.62%+51.94%+166.83% 1,006B
+3.99%+10.10%+67.53%+55.63% 589B
+4.20%+10.15%+35.63%+87.74% 430B
-0.66%+5.11%+29.26%+21.27% 331B
+1.82%+8.85%+39.72%+25.35% 288B
+0.22%+6.98%+32.93%+39.24% 285B
+0.73%+13.51%-26.95%-41.57% 213B
+1.56%+3.95%+28.38%+59.45% 190B
+3.26%+2.41%+18.83%+67.03% 154B
Average +2.10%+5.36%+32.47%+84.48% 348.58B
Weighted average by Cap. +3.56%+5.38%+40.28%+79.34%

Financials

2024 2025
Net sales 1.12 0.01 0.01 0.01 0.01 0.02 0.02 0.12 0.04 0.55 0.04 0.04 1.92 -
Net income -406K -4.3K -3.77K -3.48K -3.26K -6.11K -6.23K -41.81K -16.18K -201K -16.16K -15.81K -696K -1.26M -13.36K -11.71K -10.8K -10.11K -18.95K -19.34K -130K -50.21K -623K -50.16K -49.06K -2.16M
Net Debt -9.31M -98.69K -86.53K -79.77K -74.68K -140K -143K -959K -371K -4.6M -371K -363K -15.95M -137K -1.45K -1.27K -1.17K -1.1K -2.06K -2.1K -14.11K -5.46K -67.71K -5.45K -5.33K -235K
Logo Shamrock Industrial Company Limited
Shamrock Industrial Company Limited is an India-based pharmaceuticals company. The Company offers a diverse range of manufacturing of pharmaceuticals and drugs products and allied business activities. It offers its products for various therapeutic uses, including anti-coagulants (anti-platelet), radio-protective agents, platelet regulator, anti-depressants, anti-neo plastics and immunosuppressants, antihistamines, sympathomimetics, anti-hypertensives, diuretic, anti-diabetic, calcium regulating agents, local anesthetics and anti-bacterial. Its active pharmaceutical ingredient (API) product list (manufactured) includes acenocomarol, amifostine, ciclopirox, cilazapril, losartan potassium, metaxalone, metoprolol succinate and pregabalin. The Company's API product list (contract manufactured) includes abacavir, acarbose, oxaliplatin, oxaprozin, finasteride, frusemide and colchicine.
Employees
1
Date Price Change Volume
  1. Stock Market
  2. Stocks
  3. SHAMROIN Stock